Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Aerie Pharmaceuticals Company Profile (NASDAQ:AERI)

Consensus Ratings for Aerie Pharmaceuticals (NASDAQ:AERI) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $35.50 (63.59% upside)

Analysts' Ratings History for Aerie Pharmaceuticals (NASDAQ:AERI)
Show:
DateFirmActionRatingPrice TargetDetailsShare
7/17/2014RBC CapitalBoost Price TargetOutperform$36.00 -> $41.00ViewTweet This Rating  Share This Rating on StockTwits
7/3/2014Canaccord GenuityInitiated CoverageBuy$40.00ViewTweet This Rating  Share This Rating on StockTwits
6/26/2014RBC CapitalBoost Price TargetOutperform$27.00 -> $36.00ViewTweet This Rating  Share This Rating on StockTwits
6/26/2014Needham & Company LLCBoost Price TargetBuy$26.00 -> $37.00ViewTweet This Rating  Share This Rating on StockTwits
5/13/2014RBC CapitalLower Price TargetOutperform$28.00 -> $27.00ViewTweet This Rating  Share This Rating on StockTwits
3/19/2014Stifel NicolausBoost Price TargetPositive -> Buy$22.00 -> $24.00ViewTweet This Rating  Share This Rating on StockTwits
3/19/2014RBC CapitalBoost Price TargetOutperform$25.00 -> $28.00ViewTweet This Rating  Share This Rating on StockTwits
3/19/2014Needham & Company LLCBoost Price TargetBuy$22.00 -> $26.00ViewTweet This Rating  Share This Rating on StockTwits
12/3/2013Needham & Company LLCInitiated CoverageBuy$18.00ViewTweet This Rating  Share This Rating on StockTwits
11/19/2013Canaccord GenuityInitiated CoverageBuy -> Buy$19.00ViewTweet This Rating  Share This Rating on StockTwits
11/19/2013RBC CapitalInitiated CoverageOutperform$20.00ViewTweet This Rating  Share This Rating on StockTwits
11/19/2013Stifel NicolausInitiated CoverageBuy$18.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 7/22/2012 forward)